Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07316166 · ClinicalTrials.gov registry record · Phase 4

Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine

A Phase 4 study of Postoperative Pain Management, sponsored by Rhode Island Hospital.

Recruiting
Registry status
Phase 4
Development phase
120
Enrollment target
1
Study location

NCT07316166 is a Phase 4 study of Postoperative Pain Management that is actively recruiting participants, run by Rhode Island Hospital. The registered enrollment target is 120 participants, below the 135-participant average among 5 other Postoperative Pain Management trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07316166, a Phase 4 study of Postoperative Pain Management, is actively recruiting participants, sponsored by Rhode Island Hospital.

RECRUITING
Registry status
Phase 4
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.

Interventions

  • DRUG Dexmedetomidine
  • DRUG Ropivacaine

Study Locations (1)

Rhode Island

  • The Miriam Hospital - Providence

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-12-08
Est. Completion 2027-06
Phase Phase 4

Sponsor

Rhode Island Hospital

130 total trials

What the Registry Record Tells You About NCT07316166

The ClinicalTrials.gov registry entry for NCT07316166 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 5 other Postoperative Pain Management trials with a reported enrollment target (11% lower). The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postoperative Pain Management appearing as the primary indexed condition, and to 2 interventions - of which Dexmedetomidine is the first listed.

NCT07316166 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT07316166 about?

NCT07316166 is a clinical study titled "Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine". The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.

What is the current status of trial NCT07316166?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2025-12-08. Estimated completion is 2027-06.

What conditions does trial NCT07316166 study?

This clinical trial studies the following conditions: Postoperative Pain Management.

What interventions are being tested in trial NCT07316166?

The interventions under investigation include: Dexmedetomidine (DRUG), Ropivacaine (DRUG).

Who is sponsoring clinical trial NCT07316166?

This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07316166 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postoperative Pain Management

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.